eng URI http://hdl.handle.net/10795/3043 βιοχημεία καρκίνος πρόληψη των ασθενειών Prostate cancer (PCa) is one of the leading causes of cancer death among males, especially in more developed countries. Diagnosis is often achieved at an early stage of the disease with prostate biopsy, following a screening test showing elevated serum levels of prostate-specific antigen or a positive digital rectal examination. Early detection of PCa has led to a substantial decline in the number of metastatic patients. However, the prostate-specific antigen screening test has proved to be a double-edged sword so far, as it also accounts for PCa overdiagnosis. Due to the variability of PCa features, accurate prognosis of PCa patients is very important for determining treatment options. Therefore, this review focuses on the most promising prognostic and predictive biomarkers in PCa, which are likely to play a pivotal role, alone or in panels, in the personalized medicine era that has recently emerged. 10 pp. LOMv1.0 creator LOMv1.0 publisher LOMv1.0 Scientific Coordinator LOMv1.0 Project Final Beneficiary LOMv1.0 Project Executing Organisation 2015 Digital Library of the Operational Programme "Education and Lifelong Learning" abstract types Text Androgen receptor Kallikrein-related peptidase KLK miRNA PCA3 Prognosis Prostate carcinoma Prostate-specific antigen PSA Tumor marker 252365 application/pdf http://repository.edulll.gr/edulll/bitstream/10795/3043/2/3043_EXPE%23HKL.pdf Άρθρο ανασκόπησης (review) Expert Rev Mol Diagn. 2015;15(12):1567-76 URI http://hdl.handle.net/10795/3043 LOMv1.0creator 2016-05-05T16:54:27Z LOMv1.0validator 2016-05-05T16:54:27Z LOMv1.0 gre no no Copyright EYD-EPEDBM (Operational Programme "Education and Lifelong Learning")